TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1247149

Group type: EXPERIMENTAL
Intervention: 10 cm reversed jejunal segment
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Reversal placed at the gastric outlet
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Reversal placed just below the ligament of Treitz
Number of subjects: 11
Study: 30688377

Group type: EXPERIMENTAL
Intervention: Reciproc
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ProTaper Next (PTN)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: WaveOne Gold (WOG)
Number of subjects: 40

Group type: COMPARATOR
Intervention: ProDesign Logic (PDL)
Number of subjects: 40
Study: 27646508

Group type: EXPERIMENTAL
Intervention: Lottery-based incentive
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Traditional direct payment incentive
Number of subjects: 191

Group type: COMPARATOR
Intervention: Control (daily feedback without any incentive)
Number of subjects: 191
Study: 26098793

Group type: EXPERIMENTAL
Intervention: Continuation-phase cognitive therapy (C-CT)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLX)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Pill placebo (PBO)
Number of subjects: 241
Study: 23786536

Group type: EXPERIMENTAL
Intervention: Eplerenone (100 mg/day) for 1 month
Number of subjects: 22
Study: 21930542

Group type: EXPERIMENTAL
Intervention: Intraosseous needle (ION) placement
Number of subjects: 40

Group type: COMPARATOR
Intervention: Umbilical venous catheter (UVC) placement
Number of subjects: 40
Study: 18359910

Group type: EXPERIMENTAL
Intervention: Low-intensity pulsed ultrasound
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diagnostic ultrasound exposure during pregnancy
Number of subjects: 0
Study: 16374892

Group type: EXPERIMENTAL
Intervention: Yoga program
Number of subjects: 38
Study: 14636905

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg/day titrated to 80 mg/day
Number of subjects: 623

Group type: COMPARATOR
Intervention: Atorvastatin 20 mg/day titrated to 80 mg/day
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 and 80 mg
Number of subjects: 623

Group type: COMPARATOR
Intervention: Atorvastatin 80 mg
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Both treatments (Rosuvastatin and Atorvastatin)
Number of subjects: 623
Study: 11000355

Group type: EXPERIMENTAL
Intervention: Warmed carbon dioxide gas (37 degrees C)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Room-temperature carbon dioxide gas (21 degrees C)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups (Warmed and Cold)
Number of subjects: 20
Study: 8626819

Group type: EXPERIMENTAL
Intervention: High calcium intake (60.4 ± 6.5 mmol/day [2414 ± 260 mg/day]; n = 13)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Usual calcium intake (20.4 ± 7.2 mmol/day [815 ± 289 mg/day]; n = 15)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Young group (12 normal young adult women, age 30.1 ± 4.4 years)
Number of subjects: 28
Study: 1589234

Group type: EXPERIMENTAL
Intervention: Intranasal salmon calcitonin (3 x 100 U/day)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo (3 sprays)
Number of subjects: 66
Study: 2424102

Group type: EXPERIMENTAL
Intervention: Radiotherapy plus weekly injection of bleomycin 15 mg and mitomycin C 4 mg
Number of subjects: 300

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 300
Study: 29641281

Group type: EXPERIMENTAL
Intervention: TissueGene‐C (TG‐C)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study: 27263311

Group type: EXPERIMENTAL
Intervention: Horizontal position (Group I)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Trendelenburg position 5 degrees (Group II)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Trendelenburg position 10 degrees (Group III)
Number of subjects: 180

Group type: COMPARATOR
Intervention: All groups (I, II, III)
Number of subjects: 180
Study: 24113564

Group type: EXPERIMENTAL
Intervention: Positive affect intervention (LEAF)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 24
Study: 22765917

Group type: EXPERIMENTAL
Intervention: Aspirin (20mg/kg) administered at 0h, 3h, or 24h after SE, followed by once daily treatment for 20 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin (20mg/kg) administered after SE
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin (20mg/kg) administered at 3h or 24h after SE
Number of subjects: 0
Study: 20705277

Group type: EXPERIMENTAL
Intervention: Cognate words
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control matched words
Number of subjects: 0
Study: 18822175

Group type: EXPERIMENTAL
Intervention: Nerve root decompression according to Gill (unilateral or bilateral)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Instrumented spondylodesis (pedicle screw fixation with interbody fusion)
Number of subjects: 0
Study: 15828938

Group type: EXPERIMENTAL
Intervention: LyphoDerm + standard care (hydrocolloid dressing and compression therapy)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Standard care + vehicle
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: LyphoDerm + standard care (hydrocolloid dressing and compression therapy) in patients with enlarging ulcers
Number of subjects: 194

Group type: COMPARATOR
Intervention: Standard care + vehicle in patients with enlarging ulcers
Number of subjects: 194
Study: 12424538

Group type: EXPERIMENTAL
Intervention: Recombinant human G‐CSF (Lenograstim) 263 micro g/day SC starting from day 12 (Group 1)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Recombinant human G‐CSF (Lenograstim) 263 micro g/day SC starting from day 17 (Group 2)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Historical control group (no G‐CSF)
Number of subjects: 55
Study: 10638406

Group type: EXPERIMENTAL
Intervention: Technetium-99m-tetrofosmin
Number of subjects: 101

Group type: COMPARATOR
Intervention: Technetium-99m-MIBI
Number of subjects: 101
Study: 7549803

Group type: EXPERIMENTAL
Intervention: Control diet plus soy foods
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Control diet plus carotenoid-rich vegetables
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Control diet plus cruciferous vegetables
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control diet alone
Number of subjects: 19
Study: 1659172

Group type: EXPERIMENTAL
Intervention: High-carbohydrate, high-fiber diet (HCHF)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low-carbohydrate, low-fiber diet (LCLF)
Number of subjects: 10
Study: 7048863

Group type: EXPERIMENTAL
Intervention: AMCA (tranexamic acid)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control
Number of subjects: 105
Study: 30554611

Group type: EXPERIMENTAL
Intervention: Intermittent exercise-heat exposures (IHE) every fifth day for 25 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (CON) that exercised in a temperate environment (24°C, 21%RH)
Number of subjects: 16
Study: 30027496

Group type: EXPERIMENTAL
Intervention: Tolcapone (200 mg)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 27552463

Group type: EXPERIMENTAL
Intervention: Modified PITT technique
Number of subjects: 8

Group type: COMPARATOR
Intervention: Interference screw technique
Number of subjects: 8
Study: 24796970

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine (LDX) 30, 50, or 70 mg/day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine (LDX)
Number of subjects: 30
Study: 21476945

Group type: EXPERIMENTAL
Intervention: Nurse-managed home telehealth intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-intensity remote monitoring
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 0
Study: 19848574

Group type: EXPERIMENTAL
Intervention: Insulin aspart applied with the FlexPen (IAFP)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Pulmonary human insulin applied with the Exubera device (HIEX)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: FlexPen
Number of subjects: 12

Group type: COMPARATOR
Intervention: Exubera
Number of subjects: 12
Study: 17567421

Group type: EXPERIMENTAL
Intervention: Intrauterine vesicoamniotic shunting for fetal bladder outflow obstruction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conservative, noninterventional care (expectant management)
Number of subjects: 0
Study: 15502026

Group type: EXPERIMENTAL
Intervention: Atracurium (0.5 mg/kg)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Cisatracurium (0.15 mg/kg)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Atracurium and Cisatracurium
Number of subjects: 87
Study: 11207172

Group type: EXPERIMENTAL
Intervention: Immediate zidovudine
Number of subjects: 195

Group type: COMPARATOR
Intervention: Deferred zidovudine (matching placebo)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: All children regardless of original allocation
Number of subjects: 195
Study: 9576371

Group type: EXPERIMENTAL
Intervention: 1.1% amino acid dialysis solution (Nutrineal)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 1.5% dextrose Dianeal
Number of subjects: 20
Study: 7932287

Group type: EXPERIMENTAL
Intervention: Substance use
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Functional status
Number of subjects: 100
Study: 2979240

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31826682

Group type: COMPARATOR
Intervention: csDMARDs
Number of subjects: 306
Study: 29972210

Group type: EXPERIMENTAL
Intervention: Intervention group (n=20) consuming a daily 200mL liquid juice containing 3000mg omega-3 PUFAs, 10μg vitamin D3, 150mg resveratrol, and 8g whey protein isolate
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo group (n=17) consuming a daily 200mL juice only
Number of subjects: 37
Study: 27413129

Group type: EXPERIMENTAL
Intervention: Behavior change intervention
Number of subjects: 248

Group type: COMPARATOR
Intervention: Control
Number of subjects: 248
Study: 25601244

Group type: EXPERIMENTAL
Intervention: Scenario-based simulation course training
Number of subjects: 116

Group type: COMPARATOR
Intervention: Traditional course
Number of subjects: 116
Study: 23876590

Group type: EXPERIMENTAL
Intervention: Imidafenacin (0.1 mg) twice daily
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo twice daily
Number of subjects: 46
Study: 19788433

Group type: EXPERIMENTAL
Intervention: Capsulin 150U
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Capsulin 300U
Number of subjects: 16

Group type: COMPARATOR
Intervention: Actrapid 12U
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Capsulin (150U twice daily during repeat dosing)
Number of subjects: 16
Study: 19025390

Group type: EXPERIMENTAL
Intervention: Viewing procedure real-time on the video monitor
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no viewing of the screen)
Number of subjects: 100
Study: 16487438

Group type: EXPERIMENTAL
Intervention: Euthyroid group (L‐thyroxine plus placebo)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Low‐TSH group (L‐thyroxine)
Number of subjects: 24
Study: 12964065

Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg daily
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Risedronate
Number of subjects: 26
Study: 11083213

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Open classic technique
Number of subjects: 30
Study: 9200848

Group type: EXPERIMENTAL
Intervention: 1,2,4‐TMB alone
Number of subjects: 9

Group type: COMPARATOR
Intervention: White spirit
Number of subjects: 9
Study: 1487561

Group type: EXPERIMENTAL
Intervention: Venlafaxine 25 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Venlafaxine 75 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Venlafaxine 150 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: O-desmethylvenlafaxine (active metabolite)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Composite parameter (AUC + activity factor.AUCm)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Venlafaxine and O-desmethylvenlafaxine
Number of subjects: 18
Study: 3161013

Group type: EXPERIMENTAL
Intervention: Ketanserin (mean dose 71 mg/d)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31326345

Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation (FMT) capsules (75 capsules over 3 days, each containing approximately 0.38 g of minimally processed donor stool)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo capsules (75 capsules over 3 days)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Adverse events during FMT
Number of subjects: 48
Study: 29953740

Group type: EXPERIMENTAL
Intervention: High-fat diet and liraglutide treatment (HFL)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Chow diet (HFC)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combined liraglutide and dietary intervention (HFCL)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Continued high-fat diet (HF)
Number of subjects: 40
Study: 25637044

Group type: EXPERIMENTAL
Intervention: rhBNP
Number of subjects: 116

Group type: COMPARATOR
Intervention: Nitroglycerin (NIT)
Number of subjects: 116
Study: 23760610

Group type: EXPERIMENTAL
Intervention: Telephone counseling (TC)
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Face-to-face counseling (FC)
Number of subjects: 625

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 625
Study: 22861074

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 127

Group type: COMPARATOR
Intervention: No sedation
Number of subjects: 127
Study: 19828592

Group type: EXPERIMENTAL
Intervention: Full-time wear (30 patients)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Part-time wear (32 patients)
Number of subjects: 62
Study: 17888806

Group type: EXPERIMENTAL
Intervention: Problem-solving therapy plus usual care (PST-UC)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Psychiatric consultation plus usual care (PC-UC)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 254
Study: 15050906

Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg daily
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 11576036

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 71

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 71
Study: 9819368

Group type: EXPERIMENTAL
Intervention: Yohimbine (YHO)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Clonidine (CLO)
Number of subjects: 16
Study: 8619339

Group type: EXPERIMENTAL
Intervention: Brofaromine (150 mg/day)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 2711992

Group type: EXPERIMENTAL
Intervention: Diltiazem (240 or 360 mg/day)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 18957

Group type: EXPERIMENTAL
Intervention: 3 mg oral carbuterol
Number of subjects: 26

Group type: COMPARATOR
Intervention: 35 mg ephedrine sulfate
Number of subjects: 26
Study: 31482633

Group type: EXPERIMENTAL
Intervention: 2% Zanthoxylum bungeanum maxim extract
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vehicle formulation
Number of subjects: 20
Study: 28095938

Group type: EXPERIMENTAL
Intervention: Patient communication group (received the patient‐to‐patient communication model)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Physician communication group
Number of subjects: 65

Group type: COMPARATOR
Intervention: Routine communication group
Number of subjects: 65
Study: 25816713

Group type: EXPERIMENTAL
Intervention: atenolol (25-50 mg)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: bisoprolol (2.5-5 mg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: both drugs
Number of subjects: 19
Study: 23283255

Group type: EXPERIMENTAL
Intervention: Lidocaine 0.25 mg/kg
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Lidocaine 0.5 mg/kg
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 91
Study: 20723985

Group type: EXPERIMENTAL
Intervention: PAPP-A levels ≥ 11.33 mIu/L
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: PAPP-A levels < 11.33 mIu/L
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein levels
Number of subjects: 129
Study: 20077989

Group type: EXPERIMENTAL
Intervention: Comprehensive Nursing Rehabilitation Program (CNRP)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Capacity Intervention (improving strength and balance)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Performance Intervention (fostering daily mobility and activity)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Facilitating Intervention (providing education, support, and stress management)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CNRP overall
Number of subjects: 24
Study: 17259484

Group type: EXPERIMENTAL
Intervention: Vildagliptin (100 mg daily, divided doses)
Number of subjects: 786

Group type: COMPARATOR
Intervention: Rosiglitazone (8 mg daily, once daily)
Number of subjects: 786
Study: 15634825

Group type: EXPERIMENTAL
Intervention: 5 mg of methadone
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: 5 mg of morphine
Number of subjects: 65

Group type: COMPARATOR
Intervention: 0.5 mL of saline solution
Number of subjects: 65
Study: 12059047

Group type: EXPERIMENTAL
Intervention: AIT-082 (0.6, 2.0, 6.0, and 20.0 mg/kg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 10435265

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study: 7733089

Group type: EXPERIMENTAL
Intervention: Nipradilol 6 mg twice a day (n = 14)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (n = 6)
Number of subjects: 20
Study: 2209498

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis (Cefotaxime 2 g i.v. 15 min before the procedure)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (no antibiotic prophylaxis)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study: 7421359

Group type: EXPERIMENTAL
Intervention: Quinine sulphate (300 mg capsule)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 26787360

Group type: EXPERIMENTAL
Intervention: CALM intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study: 28259500

Group type: EXPERIMENTAL
Intervention: Family Check‐up (FCU)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Psychoeducation (PE)
Number of subjects: 92
Study: 25890296

Group type: COMPARATOR
Intervention: PVP (group 1, n=37)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: MIPS combined with PVP (group 2, n=31)
Number of subjects: 68
Study: 24063212

Group type: EXPERIMENTAL
Intervention: Tongjiang Granule (TJG), 10 g each time, three times a day for 4 weeks
Number of subjects: 128

Group type: COMPARATOR
Intervention: Omeprazole Tablet, 20 mg each time, two times a day for 4 weeks
Number of subjects: 128
Study: 21370966

Group type: EXPERIMENTAL
Intervention: Coenzyme Q(10) (200 mg/day)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51

Group type: COMPARATOR
Intervention: Coenzyme Q(10) (200 mg/day) vs Placebo
Number of subjects: 51
Study: 19647175

Group type: EXPERIMENTAL
Intervention: Lymphoseek (1.0 nmol)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Tc-99m-sulfur colloid (TcSC)
Number of subjects: 11
Study: 17722619

Group type: EXPERIMENTAL
Intervention: Rectal suppositories vitaprost forte
Number of subjects: 0
Study: 15104911

Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy (CBT) delivered by videoconference
Number of subjects: 21

Group type: COMPARATOR
Intervention: Cognitive-behavior therapy (CBT) delivered face-to-face
Number of subjects: 21
Study: 11361049

Group type: EXPERIMENTAL
Intervention: GW420867X 100 mg (fasted state)
Number of subjects: 15

Group type: COMPARATOR
Intervention: GW420867X 100 mg (high-fat meal)
Number of subjects: 15

Group type: COMPARATOR
Intervention: GW420867X 100 mg (normal fat meal)
Number of subjects: 15
Study: 10025066

Group type: EXPERIMENTAL
Intervention: Protective stenting (Palmaz‐Schatz stents) after successful recanalization of TCO
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional PTCA (without protective stenting)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Protective stenting
Number of subjects: 100
Study: 7986784

Group type: EXPERIMENTAL
Intervention: Soymilk
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Concentrated soya-bean-protein solution (isolate)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Water
Number of subjects: 8
Study: 2915537

Group type: EXPERIMENTAL
Intervention: Peripheral vascular patients (N = 15)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Disease‐free controls (N = 9)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups (Cases and Controls)
Number of subjects: 24
Study: 789380

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (200 milligrams three times a day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 29878264

Group type: EXPERIMENTAL
Intervention: Surfactant lung lavage (SLL)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No lung lavage (NLL)
Number of subjects: 60
Study: 28805759

Group type: EXPERIMENTAL
Intervention: Long-acting pentoxifylline (vasonite) in combined therapy
Number of subjects: 36
Study: 26125259

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX-A) treatment
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX-A) treatment combined with orthopedic joint brace
Number of subjects: 105

Group type: COMPARATOR
Intervention: Oral medications
Number of subjects: 105
Study: 23042612

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) - seven individual sessions concurrent with radiotherapy
Number of subjects: 35

Group type: COMPARATOR
Intervention: Non-directive supportive counseling (SC) - seven individual sessions concurrent with radiotherapy
Number of subjects: 35
Study: 21705562

Group type: EXPERIMENTAL
Intervention: Bicruciate-stabilised TKR
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Posterior-stabilised TKR
Number of subjects: 28

Group type: COMPARATOR
Intervention: Pre-operative knees
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28